Asklepios BIoPharmaceutical   Report issue

For profit Phase 2
Founded: Chapel Hill NC United States (2003)
Status: Acquired by Bayer (2020)

Organization Overview

First Clinical Trial
2018
NCT03533673
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Actus Therapeutics, Inc. | Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)

Active Ingredients

Drugs in Phase 2 Trials (2)

aav2/8lsphgaa (1 trial)

bv-101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glycogen Storage Disease Type II (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2